This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes
by Zacks Equity Research
As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.
Here's Why You Should Hold on to Intuitive Surgical Stock Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on robust domestic growth as well as solid second-quarter of fiscal 2020 results.
AMN Healthcare (AMN) Introduces New Customizable Offering
by Zacks Equity Research
AMN Healthcare (AMN) offers a customizable return-to-work solutions as businesses resume operations amid the ongoing pandemic.
Abbott's (ABT) FreeStyle Libre Study Outcome Favorable
by Zacks Equity Research
The latest study outcome aligns with the American Diabetes Association's recommended A1c level of 7% for adults with diabetes.
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about LabCorp (LH) on increasing demand for COVID-19 tests as well as robust first-quarter 2020 results.
Zacks.com featured highlights include: eBay, Quest Diagnostics, Acuity Brands and Vistra Energy
by Zacks Equity Research
Zacks.com featured highlights include: eBay, Quest Diagnostics, Acuity Brands and Vistra Energy
Skip the Market Blip, Ride Next Rally With 4 Buy-Rated Picks
by Aniruddha Ganguly
Here we pick four stocks that score as buying opportunities, despite their loss of value in the past week, on the back of strong fundamentals, prospects and optimism over a speedy U.S. economy revival.
4 Stocks With Upgraded Broker Ratings Worth Betting on Now
by Swayta Shah
By following broker ratings, you can find stocks that are likely to generate solid returns.
Diagnostic Testing Remains Crucial in Combatting Coronavirus
by Trina Mukherjee
Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.
DGX vs. EHC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DGX vs. EHC: Which Stock Is the Better Value Option?
Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA
by Zacks Equity Research
This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.
Why Is Quest Diagnostics (DGX) Up 12.3% Since Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Info Systems Outlook Bright Amid Coronavirus Crisis
by Urmimala Biswas
Despite the coronavirus-led worldwide sales disruption, Medical Info Systems is one of the few sectors witnessing industry-wide growth.
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
by Zacks Equity Research
Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Quest Diagnostics (DGX) in Focus: Stock Moves 5.4% Higher
by Zacks Equity Research
Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.
Quest Diagnostics (DGX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 13.25% and 4.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will COVID-19 Test Aid Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) recently-launched COVID-19 test service anticipated to have contributed to Q1 revenues.
3 Stocks Testing The Coronavirus
by Daniel Laboe
If we can test the working population, we will be able to bring the healthy American's back to work and isolate those with the virus
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
Bruker Inks Deal to Distribute Coronavirus Detection Test
by Zacks Equity Research
The agreement would make Bruker (BRKR) a key player in coronavirus diagnosis.